Fate Therapeutics (FATE) USD0.001
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an ideal source for creating cell therapy product candidates. The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.